BioSpace News Archive

Centinel Spine®, LLC, the leading global medical device company addressing cervical and lumbar spinal disease with the most clinically-proven total disc replacement technology platform in the world, announced record third quarter 2023 prodisc TDR financial results.

MaaT Pharma announced that extended results from its Early Access Program of MaaT013 in 111 patients with aGvHD and the design of its Phase 2b study evaluating MaaT033 in improving overall survival in patients undergoing allogenic hematopoietic cell transplantation have been selected for poster presentations at the 65th American Society of Hematology Annual Meeting held from December 9-12, 2023, in San Diego, California, USA.

TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that it has selected of Fortrea as the Company’s Contract Research Organization for global trials, including ACHIEVE and ACHIEVE2.

Fluent BioSciences is excited to announce a partnership with Singular Genomics, a company leveraging novel next-generation sequencing and multiomics technologies to empower researchers and clinicians.

Avenue Therapeutics, Inc. announced the closing of its previously announced public offering of an aggregate of 16,633,400 units at a public offering price of $0.3006 per unit.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 52,500 restricted stock units of Arcutis’ common stock to eight newly hired employees.

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the third quarter 2023.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

IN8bio, Inc. announced an abstract detailing new, positive data from the Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies has been selected for poster presentation at the 65th American Society of Hematology Annual Meeting and Exposition taking place December 9-12, 2023.